|
HepC Newsletter
|
Dema-@aol.com
|
Oct 16, 2009 08:03 PDT
|
NATAP _http://natap.org/_ (http://natap.org/)
_______________________________________________
Alios BioPharma Issued Broad U.S. Patent for Glyco-Engineered Interferons
SOUTH SAN FRANCISCO, CA -- 10/16/09 -- Alios BioPharma, Inc. announced
today that the U.S. Patent and Trademark Office issued U.S. Patent No.
7,597,884, claiming numerous compounds from the company's glycoengineering program
including its IND candidate, Glycoferon™, which is being developed for the
treatment of chronic hepatitis C. The patent, titled "Hyperglycosylated
Polypeptide Variants and Methods of Use" and issued on October 6, 2009, is the
first patent granted to Alios BioPharma for the company's proprietary
approach for glycoengineering of proteins including type 1 interferons.
"This patent represents a significant milestone for Alios as the method for
glycoprotein-engineering of interferons is being applied to the
development of an interferon alpha (Glycoferon™) molecule, which may be useful for
the treatment of chronic hepatitis C, and an interferon beta (Beta-Gly™)
molecule, which may be useful for the treatment of relapsing remitting multiple
sclerosis. Both of these compounds have the potential for once monthly
dosing without compromising biological potency," commented Leonid M.
Beigelman, Ph.D., Executive Vice President, Research of Alios BioPharma, Inc.
Less frequent dosing of a treatment for chronic diseases such as hepatitis
C and relapsing remitting multiple sclerosis has many potential benefits,
including the possibility for increased patient compliance potentially
leading to better tolerability and increased efficacy.
The company will present its preclinical results for the Glycoferon
program, including efficacy in a yellow fever virus model (a surrogate model for
chronic hepatitis C), at the American Association for the Study of Liver
Diseases (AASLD) conference to be held October 30 through November 3 in
Boston. The poster, "Significant improvement of the pharmacokinetic profile of a
hyper-glycosylated consensus type 1 interferon," will be presented on
November 3rd between 8 am and 1 pm by Alios senior scientist Jin Hong, Ph.D.
About Alios BioPharma
Alios BioPharma, Inc., an emerging biotechnology company headquartered in
South San Francisco, California, is developing novel medicines to treat
viral diseases by activating pathways in the innate immune system. Alios is
developing small-molecule and protein therapeutics addressing major market
opportunities.
Contacts:
Debra Bannister (media)
Communications Consultant
530 676-8001
Alios BioPharma
Bruce Bryan
MBA (corporate)
Senior Director of Operations and Project Management
650 635-5502
_pr-@aliosbiopharma.com_ (mailto:pre-@aliosbiopharma.com)
***************
This Essential Disease and Therapy Review on Hepatitis C Provides a
Comprehensive Overview of the Disease, Diagnosis and Treatment
_http://www.reuters.com/article/pressRelease/idUS99883+14-Oct-2009+BW2009101
4_
(http://www.reuters.com/article/pressRelease/idUS99883+14-Oct-2009+BW20091014)
GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral
Clearance And Increases RVR Rates In Phase 2 Clinical Trial
_http://www.natap.org/2008/AASLD/AASLD_08.htm_
(http://www.natap.org/2008/AASLD/AASLD_08.htm)
|
|
 |
|
